HC Wainwright & Co. Maintains Buy on Neurogene, Raises Price Target to $55
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has maintained a Buy rating on Neurogene (NASDAQ:NGNE) and increased the price target from $45 to $55.
March 19, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Neurogene and raises the price target from $45 to $55.
The increase in price target by a reputable analyst firm like HC Wainwright & Co. typically signals a strong bullish outlook on the stock, suggesting a positive short-term impact on Neurogene's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100